{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:13Z","timestamp":1792123093314,"version":"4.4.0"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamadermatol.2018.4118","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T11:39:05Z","timestamp":1544614745000},"page":"221","source":"Crossref","is-referenced-by-count":20,"title":["Association of Noninfectious Pneumonia With Ustekinumab Use"],"prefix":"10.1001","volume":"155","author":[{"given":"Allen","family":"Brinker","sequence":"first","affiliation":[{"name":"Office of Surveillance and Epidemiology, Division of Pharmacovigilance, FDA Center for Drug Evaluation and Research, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Division of Pharmacovigilance, FDA Center for Drug Evaluation and Research, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Chan","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Division of Pharmacovigilance, FDA Center for Drug Evaluation and Research, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"32","key":"dbr180029r2","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1183\/09031936.01.18s320002","article-title":"Interstitial lung diseases: an epidemiological overview.","volume":"32","author":"Demedts","year":"2001","journal-title":"Eur Respir J Suppl"},{"key":"dbr180029r3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease.","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir Med J"},{"issue":"5","key":"dbr180029r6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5152\/TJAR.","article-title":"Stop being so sensitive: an exceptionally rare report of ustekinumab-induced sub-acute hypersensitivity pneumonitis.","volume":"45","author":"Ali","year":"2017","journal-title":"Turk J Anaesthesiol Reanim"},{"key":"dbr180029r7","first-page":"A6584","article-title":"Organizing pneumonia in a young patient being treated with ustekinumab [Abstract].","volume":"185","author":"Teferra","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"dbr180029r8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1684\/ejd.2013.2006","article-title":"Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.","volume":"23","author":"Yashiro","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"3","key":"dbr180029r9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annder.2014.11.004","article-title":"Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis [in French].","volume":"142","author":"Amy de la Bret\u00e8que","year":"2015","journal-title":"Ann Dermatol Venereol"},{"key":"dbr180029r1","year":"2018"},{"key":"dbr180029r4","unstructured":"U.S. Food and Drug Administration. Questions and Answers on FDA's Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. Updated June 4, 2018. Accessed July 12, 2018."},{"key":"dbr180029r5","unstructured":"US Department of Health & Human Services Office for Human Research Protections. Exemptions for Public Benefit and Service Programs: OPRR Guidance on 45 CFR 46.101(b)(5). https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/guidance\/exemptions-for-public-benefit-and-service-programs\/index.html. Updated March 19, 2016. Accessed October 31, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2717575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:57:07Z","timestamp":1775303827000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.4118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.4118","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}